EDMONTON — Alberta’s new budget will carry an eye-popping $9.4-billion deficit as the province, after decades of trying to get off a roller-coaster of oil revenues, seeks to manage the ride and ...

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)Reports ...

FIGS, Inc. ( FIGS) Q4 2025 Earnings Call February 26, 2026 5:00 PM EST Good afternoon. Thank you for attending the FIGS Fourth Quarter Fiscal 2025 Earnings Conference Call. My name is Cameron, and ...

Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for ...

OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.

Q4 2025 Earnings Call February 10, 2026 4:30 PM ESTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...

SARS-CoV-2 triggers the production of the antiviral protein IFN- γ , which is associated with fatigue, muscle ache and depression. New research shows that in Long COVID patients, IFN- y production ...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.29%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.38%. Major stock indexes, ...

Bristol Myers Squibb (NYSE: BMY) today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo ...